Pfizer whiffs in PhIII study with controlled-release Lyrica

Pfizer ($PFE) fell short in the first of three Phase III studies to test a new and long-acting formulation of its drug Lyrica as an anti-seizure remedy for patients with epilepsy, the U.S. drug giant revealed on Friday. The study, which tested the formulation as a once-a-day therapy, missed its main goal of changing seizure frequency compared with placebo. Article

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.